Method for testing for allergic disease
AssigneeNational Center for Child Health and Development
InventorsNei Yoshida, Naoko Nagata, Tadahiro Oshida, Ryoichi Hashida, Yuji Sugita, Hirohisa Saito
Life of this patent
Estimating the term…
Abstract
An objective of the present invention is to provide a method for testing for an allergic disease and a method of screening for a therapeutic agent for allergic diseases. MAL was identified as a gene the expression level of which is significantly increased in T cells contained in the peripheral blood monocyte (PBMC) upon stimulation thereof with a mite allergen in vitro. The present inventors found that this gene can be used in testing for allergic diseases and in screening for agents and compounds useful in the treatment of allergic diseases.
Claims25
A method for testing for an allergic disease using MAL as an indicator gene, said method comprising the steps of:
- (a) measuring the expression level of the indicator gene in a biological sample from a subject, and
- (b) comparing the expression level measured in (a) with that in a biological sample from a normal healthy subject.
A reagent for testing for allergic disease, said reagent comprising an oligonucleotide that comprises a nucleotide sequence complementary to a polynucleotide comprising the nucleotide sequence of MAL gene or to the complementary strand thereof and that comprises at least 15 nucleotides.
A reagent for testing for allergic disease, said reagent comprising an antibody that recognizes a peptide comprising the amino acid sequence encoded by MAL gene.
A method of screening for a therapeutic agent for an allergic disease using MAL gene or a gene functionally equivalent thereto as an indicator gene, said method comprising the steps of:
- (a) contacting a candidate compound with a cell expressing the indicator gene,
- (b) measuring the expression level of the indicator gene, and
- (c) selecting a compound that reduces the expression level of the indicator gene, compared to a control.
A method of screening for a therapeutic agent for an allergic disease using MAL gene or a gene functionally equivalent thereto as an indicator gene, said method comprising the steps of:
- (a) administering a candidate compound to a test animal,
- (b) measuring the expression level of the indicator gene in a biological sample from the test animal, and
- (c) selecting a compound that reduces the expression level of the indicator gene, compared to a control.
A method of screening for a therapeutic agent for an allergic disease using MAL gene or a gene functionally equivalent thereto as an indicator gene, said method comprising the steps of:
- (a) contacting a candidate compound with a cell into which a vector comprising the transcriptional regulatory region of the indicator gene and a reporter gene that is expressed under the control of the transcriptional regulatory region has been introduced,
- (b) measuring the activity of said reporter gene, and
- (c) selecting a compound that reduces the expression level of said reporter gene, compared to a control.
A method of screening for a therapeutic agent for an allergic disease using MAL gene or a gene functionally equivalent thereto as an indicator gene, said method comprising the steps of:
- (a) contacting a candidate compound with a protein encoded by the indicator gene,
- (b) measuring the activity of said protein, and
- (c) selecting a compound that reduces the activity of said protein, compared to a control.
A therapeutic agent for an allergic disease, said agent comprising an antisense DNA against an indicator gene or a portion thereof as a principal ingredient, wherein the indicator gene is MAL gene or a gene functionally equivalent to MAL gene.
A therapeutic agent for an allergic disease, said agent comprising, as a principal ingredient, an antibody that binds to a protein encoded by an indicator gene, wherein the indicator gene is MAL gene or a gene functionally equivalent to MAL gene.
A method for producing an allergic disease model animal using MAL gene or a gene functionally equivalent thereto as an indicator gene, said method comprising a step of elevating expression level of the indicator gene in T cells of a non-human vertebrate.
A kit for screening for a therapeutic agent for an allergic disease, said kit comprising an oligonucleotide that comprises a nucleotide sequence complementary to a polynucleotide comprising a nucleotide sequence of an indicator gene or to the complementary strand thereof and that comprises at least 15 nucleotides and cells expressing the indicator gene, wherein the indicator gene is the MAL gene or a gene functionally equivalent to MAL gene.
A kit for screening for a therapeutic agent for an allergic disease, said kit comprising an antibody that recognizes a peptide comprising an amino acid sequence encoded by an indicator gene and cells expressing the indicator gene, wherein the indicator gene is MAL gene or a gene functionally equivalent to MAL gene.
A method for treating an allergic disease, said method comprising the step of administering an antisense DNA against MAL gene, a gene functionally equivalent to MAL gene, or a portion thereof.
A method for treating an allergic disease, said method comprising the step of administering an antibody that binds to a protein encoded by MAL gene.
Dependencies are inferred from the claim text.